Isabelle Ray‐Coquard

Research interests

Publications

• ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2023.11.015

• Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.07.011

• Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer

  Nature · 2023 · https://doi.org/10.1038/s41586-023-06367-z

• Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00073-5

• European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.11.013

• ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.08.2102

• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz062

• Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1911361

• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz062

• Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30469-2

• Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group

  European Journal of Cancer · 2017 · https://doi.org/10.1016/j.ejca.2017.06.017

• Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30381-9

• Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30469-2

• Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30559-9

• Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France

  European Journal of Cancer · 2016 · https://doi.org/10.1016/j.ejca.2016.02.008

• Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00075-9

• Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2013.51.4489

• The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds203

• Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

  BMC Cancer · 2011 · https://doi.org/10.1186/1471-2407-11-72

• Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

  The Lancet Oncology · 2010 · https://doi.org/10.1016/s1470-2045(10)70222-9

• Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

  Cancer Research · 2009 · 10.1158/0008-5472.can-08-3845

• Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

  Cancer · 2009 · https://doi.org/10.1002/cncr.24149

• Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

  The Lancet · 2009 · https://doi.org/10.1016/s0140-6736(09)60502-x

• Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

  Cancer Research · 2009 · https://doi.org/10.1158/0008-5472.can-08-2360

• Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2008.17.3146

• Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2006.09.0183

• Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

  Annals of Oncology · 2005 · https://doi.org/10.1093/annonc/mdi127

Current projects

No projects listed.